Scientific Poster: Application of Real-Time Live Cell Imaging in the Development of Antibody-Drug Conjugates

Access our scientific poster from Drug Discovery 2024

At Drug Discovery 2024, Abzena’s Robert Francis PhD presented our latest poster entitled: ‘Application of Real-Time Live Cell Imaging in the Development of Antibody-Drug Conjugates’.

This poster shows how Abzena provide live cell imaging expertise within our diverse range of offerings in developing and progressing antibody-drug conjugates (ADCs) and other complex biologics.

Abstract

Antibody-Drug Conjugates (ADCs) have rapidly become an important class of targeted therapeutics against cancer, delivering both the specificity of mAbs and the cytotoxicity of small molecule drugs. Continual developability assessment underpins all aspects of ADC drug discovery and development and the appropriate use of real- time live cell imaging as part of the developability assessment of ADCs can play a significant role in the selection of candidates with the greatest chance of clinical success. The versatility that live cell imaging provides, either through the Incucyte or higher resolution spinning disk confocal microscopy, can be harnessed to capture the fundamental characteristics of successful drug design and increases the likelihood of obtaining a successful therapeutic candidate.

Poster authors include: Robert Francis, Natasha Carter, Grant Harradence, Robert Cunningham, Nathan Shaw, Adele Kinsey, Maryam Ahmadi, Erika Kovacs, Robert Holgate, Campbell Bunce

Discover Abzena Cambridge, UK

Download Poster

Expertise in Bioassay Development

Abzena has decades of experience in developing bioassays for antibody drug conjugate (ADC) programs. Our approach focuses on developing phase-appropriate assays for the assessment of potency, efficacy, and safety, to provide our customers with the necessary tools to make effective decisions during their drug development journey to IND and beyond.

Our comprehensive bioassay solutions include both established assays and custom assay development matched to your individual program needs. In discovery, we offer target validation and hit-to-lead screening. As your program presses onward into design and developability we offer assays for specificity and tissue profiling, mode-of-action (MOAs), and immunogenicity assessments. When it comes time to manufacture your program, we can support you with potency and batch release.

For more information on how our bioassay capabilities can help your ADC program, click here.

About Abzena

Abzena is a biopharmaceutical CDMO & CRO that provides fully integrated, tailored drug design, development and manufacturing services spanning from early discovery through commercial.

Lets work together to move medicine forward.